BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24844361)

  • 21. Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.
    Ribera JM; Prawitz T; Freitag A; Sharma A; Dobi B; Rizzo F; Sabatelli L; Patos P
    Adv Ther; 2023 Jul; 40(7):3087-3103. PubMed ID: 37208556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic significance of Ph-positive acute lymphoblastic leukemia].
    Zhou L; Hu J; Chen J; Du S; Wang A; You J; Wu W; Shen Z; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):109-13. PubMed ID: 24606650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
    Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H;
    Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Shen S; Chen X; Cai J; Yu J; Gao J; Hu S; Zhai X; Liang C; Ju X; Jiang H; Jin R; Wu X; Wang N; Tian X; Pan K; Jiang H; Sun L; Fang Y; Li CK; Hu Q; Yang M; Zhu Y; Zhang H; Li C; Pei D; Jeha S; Yang JJ; Cheng C; Tang J; Zhu X; Pui CH
    JAMA Oncol; 2020 Mar; 6(3):358-366. PubMed ID: 31944221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Wassmann B; Pfeifer H; Goekbuget N; Beelen DW; Beck J; Stelljes M; Bornhäuser M; Reichle A; Perz J; Haas R; Ganser A; Schmid M; Kanz L; Lenz G; Kaufmann M; Binckebanck A; Brück P; Reutzel R; Gschaidmeier H; Schwartz S; Hoelzer D; Ottmann OG
    Blood; 2006 Sep; 108(5):1469-77. PubMed ID: 16638934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Foà R; Vitale A; Vignetti M; Meloni G; Guarini A; De Propris MS; Elia L; Paoloni F; Fazi P; Cimino G; Nobile F; Ferrara F; Castagnola C; Sica S; Leoni P; Zuffa E; Fozza C; Luppi M; Candoni A; Iacobucci I; Soverini S; Mandelli F; Martinelli G; Baccarani M;
    Blood; 2011 Dec; 118(25):6521-8. PubMed ID: 21931113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
    Vega-Ruiz A; O'Brien S; Cortes J; Kebriaei P; Thomas D; Kantarjian H; Ravandi F
    Leuk Res; 2008 Sep; 32(9):1468-71. PubMed ID: 18355919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.
    Chen H; Liu KY; Xu LP; Chen YH; Zhang XH; Wang Y; Qin YZ; Liu YR; Lai YY; Huang XJ
    Leuk Res; 2017 Aug; 59():136-141. PubMed ID: 28654842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.
    Mizuta S; Matsuo K; Yagasaki F; Yujiri T; Hatta Y; Kimura Y; Ueda Y; Kanamori H; Usui N; Akiyama H; Miyazaki Y; Ohtake S; Atsuta Y; Sakamaki H; Kawa K; Morishima Y; Ohnishi K; Naoe T; Ohno R
    Leukemia; 2011 Jan; 25(1):41-7. PubMed ID: 20944676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
    Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
    Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial.
    Ribera JM; Oriol A; González M; Vidriales B; Brunet S; Esteve J; Del Potro E; Rivas C; Moreno MJ; Tormo M; Martín-Reina V; Sarrá J; Parody R; de Oteyza JP; Bureo E; Bernal MT; ;
    Haematologica; 2010 Jan; 95(1):87-95. PubMed ID: 19797728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
    Rea D; Legros L; Raffoux E; Thomas X; Turlure P; Maury S; Dupriez B; Pigneux A; Choufi B; Reman O; Stéphane D; Royer B; Vigier M; Ojeda-Uribe M; Recher C; Dombret H; Huguet F; Rousselot P; ;
    Leukemia; 2006 Mar; 20(3):400-3. PubMed ID: 16437142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Nishii K; Sakakura M; Tsukada T; Ryuu H; Katayama N
    Int J Hematol; 2007 Apr; 85(3):273-4. PubMed ID: 17483068
    [No Abstract]   [Full Text] [Related]  

  • 36. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
    Towatari M; Yanada M; Usui N; Takeuchi J; Sugiura I; Takeuchi M; Yagasaki F; Kawai Y; Miyawaki S; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Blood; 2004 Dec; 104(12):3507-12. PubMed ID: 15315963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
    Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
    Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ribera JM; García-Calduch O; Ribera J; Montesinos P; Cano-Ferri I; Martínez P; Esteve J; Esteban D; García-Fortes M; Alonso N; González-Campos J; Bermúdez A; Torrent A; Genescà E; Mercadal S; Martínez-Lopez J; García-Sanz R
    Blood Adv; 2022 Sep; 6(18):5395-5402. PubMed ID: 35675590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.